Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Short-Term Debt: ¥1,110 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
96 GF Score
Price ¥39.38
GF Value ¥38.73
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Short-Term Debt?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 -1.67% 96 Short-Term Debt is ¥1,110 Mil as of Jun. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 96/100 and a GF Value™ of ¥38.73 (Fairly Valued). The stock has 3 warning signs investors should review.

Tibet Rhodiola Pharmaceutical Holding Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥1,110 Mil.

Tibet Rhodiola Pharmaceutical Holding Co's quarterly Short-Term Debt increased from Dec. 2025 (¥800 Mil) to Mar. 2026 (¥1,050 Mil) and increased from Mar. 2026 (¥1,050 Mil) to Jun. 2026 (¥1,110 Mil).

Tibet Rhodiola Pharmaceutical Holding Co's annual Short-Term Debt declined from Dec. 2023 (¥500 Mil) to Dec. 2024 (¥272 Mil) but then increased from Dec. 2024 (¥272 Mil) to Dec. 2025 (¥800 Mil).

Tibet Rhodiola Pharmaceutical Holding Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Tibet Rhodiola Pharmaceutical Holding Co Short-Term Debt Related Terms

Tibet Rhodiola Pharmaceutical Holding Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Short-Term Debt Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 534.66 486.10 499.99 272.17 800.27

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 692.43 966.97 800.27 1,050.36 1,110.40
SHSE:600211
96GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥1,110 Mil mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Short-Term Debt of ¥1,110 Mil as of Jun. 2026.
Is Tibet Rhodiola Pharmaceutical Holding Co's Short-Term Debt too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Short-Term Debt is ¥1,110 Mil. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Short-Term Debt compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's Short-Term Debt of ¥1,110 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Tibet Rhodiola Pharmaceutical Holding Co's current Short-Term Debt is ¥1,110 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.73, compared to a current price of ¥39.38 — trading 1.7% above its estimated fair value. The current Short-Term Debt is ¥1,110 Mil. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Short-Term Debt is ¥1,110 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be overvalued. The current stock price of ¥39.38 is trading 1.7% above its estimated GF Value™ of ¥38.73. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Short-Term Debt: ¥1,110 Mil
  • GF Value™: ¥38.73 vs. price of ¥39.38 (1.7% above fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
96GF Score

Get the complete analysis for SHSE:600211

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.38
Price
¥38.73
GF Value